Intelligent Antibiotics for an evolving threat

 

We are Viosera

 

The rise of multidrug resistant superbacteria has rendered many antimicrobials useless while millions die. We discover synergies between approved drugs and create next generation therapies. 

 

 
 
Nicholas Goldner, CEO goldner[at]viosera.com

Nicholas Goldner, CEO goldner[at]viosera.com

Christopher Bulow, COO bulow[at]viosera.com

Christopher Bulow, COO bulow[at]viosera.com

Aki Kau PhD, CSO kau[at]viosera.com 

Aki Kau PhD, CSO kau[at]viosera.com 

 
 
Steve Trampe, CFO strampe[at]owendevelopment.com

Steve Trampe, CFO strampe[at]owendevelopment.com

Gautam Dantas PhD, Chairman Scientific Advisory Board dantas[at]viosera.com

Gautam Dantas PhD, Chairman Scientific Advisory Board dantas[at]viosera.com

 
EbruYildiz_372.jpg

MRSA

Methicillin-resistant Staphylococcus aureus (MRSA) kills thousands of patients every year. MRSA skin infections can quickly become bloodstream infections. 1 in 8 septic MRSA patients loses their life to this evolving threat. Viosera is developing a therapy that could save these lives.

News & Updates

Support